IQVIA Holdings Inc. $IQV Shares Sold by Nippon Life Global Investors Americas Inc.

by · The Markets Daily

Nippon Life Global Investors Americas Inc. reduced its holdings in IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 48.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,220 shares of the medical research company’s stock after selling 2,080 shares during the period. Nippon Life Global Investors Americas Inc.’s holdings in IQVIA were worth $597,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the stock. BlackRock Inc. bought a new position in IQVIA in the second quarter worth $2,811,292,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of IQVIA by 9.0% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,634,264 shares of the medical research company’s stock worth $315,772,000 after buying an additional 134,997 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of IQVIA by 4.2% during the first quarter. Dimensional Fund Advisors LP now owns 1,657,696 shares of the medical research company’s stock valued at $282,657,000 after acquiring an additional 66,643 shares during the period. Canada Pension Plan Investment Board acquired a new stake in shares of IQVIA in the 2nd quarter valued at $240,911,000. Finally, Bank of America Corp DE acquired a new position in IQVIA in the second quarter valued at about $235,551,000. Institutional investors own 89.62% of the company’s stock.

Insider Buying and Selling

In other IQVIA news, insider James G. Berkshire sold 2,668 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total value of $697,228.44. Following the transaction, the insider directly owned 10,890 shares of the company’s stock, valued at $2,845,883.70. This represents a 19.68% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 1.70% of the company’s stock.

IQVIA Trading Down 0.1%

Shares of IQVIA stock opened at $266.93 on Monday. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.83 and a quick ratio of 0.83. The business has a fifty day simple moving average of $266.22 and a two-hundred day simple moving average of $210.41. IQVIA Holdings Inc. has a 1 year low of $154.50 and a 1 year high of $284.50. The company has a market capitalization of $43.99 billion, a price-to-earnings ratio of 32.43, a P/E/G ratio of 2.38 and a beta of 1.16.

IQVIA (NYSE:IQV – Get Free Report) last issued its quarterly earnings data on Tuesday, October 27th. The medical research company reported $3.34 earnings per share for the quarter, beating the consensus estimate of $3.26 by $0.08. The company had revenue of $4.43 billion for the quarter, compared to analyst estimates of $4.37 billion. IQVIA had a net margin of 8.05% and a return on equity of 30.02%. The company’s revenue was up 8.0% on a year-over-year basis. During the same period in the prior year, the firm earned $3.00 earnings per share. Research analysts forecast that IQVIA Holdings Inc. will post 11.53 EPS for the current year.

Wall Street Analyst Weigh In

IQV has been the subject of several research analyst reports. Mizuho boosted their price target on shares of IQVIA from $275.00 to $300.00 and gave the company an “outperform” rating in a report on Wednesday, October 7th. JPMorgan Chase & Co. increased their target price on IQVIA from $295.00 to $325.00 and gave the stock an “overweight” rating in a report on Wednesday, October 28th. Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Saturday, September 12th. Deutsche Bank Aktiengesellschaft decreased their price objective on IQVIA from $191.00 to $179.00 in a report on Thursday, October 15th. Finally, Weiss Ratings downgraded IQVIA from a “hold (c+)” rating to a “sell (d+)” rating in a research report on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $294.21.

View Our Latest Stock Analysis on IQVIA

About IQVIA

(Free Report)

IQVIA Holdings Inc is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop, commercialize and improve products by combining healthcare data with advanced analytics, consulting and technology-enabled services.

Its offerings include clinical research and trial management, real-world evidence, healthcare data and analytics, regulatory and safety services, technology platforms, and commercial solutions.

Featured Stories